Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-chloro-N-(2-(4-(2-oxopyridin-1(2H)-yl)benzamido)ethyl)thiophene-2-carboxamide is an experimental small molecule inhibitor of coagulation Factor Xa. It belongs to the benzamide class of compounds and was developed as part of a series aimed at identifying potent and selective inhibitors structurally distinct from pyrazole-based analogs. The compound has demonstrated anticoagulant activity in preclinical studies, with binding confirmed by X-ray crystallography in complex with Factor Xa. Its primary mechanism is inhibition of the serine protease activity of Factor Xa, a key enzyme in the blood coagulation cascade[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-chloro-N-(2-(4-(2-oxopyridin-1(2H)-yl)benzamido)ethyl)thiophene-2-carboxamide.